Danaher (DHR) Valuation Check After Analyst Upgrade and 2026 Earnings Recovery Narrative

Simply Wall St.12-05 00:20

Morgan Stanley’s upgrade of Danaher (DHR) has put the stock back on many watchlists, as the firm leans into a 2026 recovery story built on core revenue growth and earnings leverage. See our latest ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589839754?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349","is_english":true,"pubTime":"2025-12-05 00:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589839754","market":"hk","top_or_hot":-1,"title":"Danaher (DHR) Valuation Check After Analyst Upgrade and 2026 Earnings Recovery Narrative","media":"Simply Wall St.","content":"<div>\n<p>Morgan Stanley’s upgrade of Danaher (DHR) has put the stock back on many watchlists, as the firm leans into a 2026 recovery story built on core revenue growth and earnings leverage. See our latest ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-valuation-check-after-analyst-upgrade-and-2026-e\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Danaher (DHR) Valuation Check After Analyst Upgrade and 2026 Earnings Recovery Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDanaher (DHR) Valuation Check After Analyst Upgrade and 2026 Earnings Recovery Narrative\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-05 00:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-valuation-check-after-analyst-upgrade-and-2026-e><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Morgan Stanley’s upgrade of Danaher (DHR) has put the stock back on many watchlists, as the firm leans into a 2026 recovery story built on core revenue growth and earnings leverage. See our latest ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-valuation-check-after-analyst-upgrade-and-2026-e\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DHR.AU","symbol_name":"Dark Horse Resources","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-valuation-check-after-analyst-upgrade-and-2026-e","article_id":"2589839754","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-valuation-check-after-analyst-upgrade-and-2026-e","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2589839754","pubTimestamp":1764865242,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Morgan Stanley’s upgrade of Danaher (DHR) has put the stock back on many watchlists, as the firm leans into a 2026 recovery story built on core revenue growth and earnings leverage.\nSee our latest analysis for Danaher.\nThat optimism has helped the stock regain some momentum, with a 30 day share price return of 6.73 percent and a 90 day share price return of 14.79 percent, even though the 1 year total shareholder return is still slightly negative.\nIf Danaher’s recovery story has your...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"DHR.AU":"Dark Horse Resources","DHR":"丹纳赫"},"translate_title":"分析师升级和2026年盈利复苏叙述后丹纳赫(DHR)估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DHR.AU":1.5,"DHR":1.5},"content_text":"Morgan Stanley’s upgrade of Danaher (DHR) has put the stock back on many watchlists, as the firm leans into a 2026 recovery story built on core revenue growth and earnings leverage. See our latest analysis for Danaher. That optimism has helped the stock regain some momentum, with a 30 day share price return of 6.73 percent and a 90 day share price return of 14.79 percent, even though the 1 year total shareholder return is still slightly negative. If Danaher’s recovery story has your attention, it could be a good moment to scan other healthcare names and see which look resilient using healthcare stocks. With shares still below analysts’ targets but no longer obviously cheap after the recent rally, is Danaher quietly trading at a discount to its long term recovery potential, or is the market already pricing in that 2026 rebound? AdvertisementMost Popular Narrative: 10.1% Undervalued With Danaher last closing at $228.46 against a narrative fair value of $254.20, the story leans toward upside built on improving profitability and cash generation.  The sustained advancement of precision medicine and personalized therapies, including new AI-assisted diagnostic solutions and groundbreaking launches in genomics (like support for in vivo CRISPR therapies), positions Danaher's technology portfolio to capture higher-margin growth and drive long-term EBITDA expansion.  Read the complete narrative. Want to see what kind of revenue runway, margin lift, and earnings power this vision assumes? The full narrative lays out a bold profitability and valuation roadmap that may surprise you. Result: Fair Value of $254.20 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, lingering uncertainty around China policy shifts and prolonged biotech funding weakness could delay Danaher’s recovery trajectory and challenge those long term margin assumptions. Find out about the key risks to this Danaher narrative. Another View: Multiples Tell a Tougher Story On earnings, Danaher looks far less forgiving. The stock trades at about 46.1 times earnings versus 37 times for the wider life sciences group and a 32.7 times peer average, while its fair ratio sits nearer 32.2 times, suggesting valuation risk if sentiment normalizes. See what the numbers say about this price — find out in our valuation breakdown. NYSE:DHR PE Ratio as at Dec 2025 Build Your Own Danaher Narrative If you see the story differently or want to dig into the numbers yourself, you can build a custom view in minutes: Do it your way. A great starting point for your Danaher research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision. Ready for more investing opportunities? Before you move on, lock in your next smart idea by scanning targeted stock lists that spotlight growth, income, and innovation you will not want to overlook.  Target undervalued potential by zeroing in on companies flagged as mispriced using these 915 undervalued stocks based on cash flows so you can act before the market catches up. Focus on innovators reshaping industries through AI with these 25 AI penny stocks to keep your portfolio aligned with emerging leaders. Strengthen your income stream by pinpointing reliable payers via these 14 dividend stocks with yields > 3%, and avoid leaving attractive yields to others.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589839754","isCrawlerRequest":true}